İbrahim KÜÇÜKTÜRKMEN, Deniz BOLAT, Özgü AYDOĞDU, BÜLENT GÜNLÜSOY, TANSU DEĞİRMENCİ

ASEMPTOMATİK MİKROSKOBİK HEMATÜRİ İLE MESANE TÜMÖRÜ TANISI ARASINDAKİ İLİŞKİ

Giriş: Tekrarlayan asemptomatik mikroskobik hematüri (AMH) ile başvuran hastaların özellikle mesane kanseri (MK) öngörüsü amacıyla değerlendirilmesinde ortak bir görüş bulunmamaktadır. Bu çalışmada AMH ile başvuran yetişkin hastalarda MK’ini öngörmede etkili olabilecek potansiyel risk faktörlerini prospektif olarak ortaya konulması amaçlanmıştır. Gereç ve Yöntem: Tekrarlayan AMH’li hastaların MK’i açısından risk faktörleri olarak belirlediğimiz; yaş, cinsiyet, ailede üriner sistem tümör öyküsü olması, sigara öyküsü olması ve riskli meslek grubu verileri kaydedildi. Tüm hastalara idrar sitolojisi, üriner ultrasonografi (USG) ve sistoskopi tetkikleri yapıldı. Veriler tek değişkenli lojistik regresyon analiz testi ile analiz edildi. Tüm hipotez kontrolleri 0,05 önem seviyesinde uygulandı (p

THE RELATIONSHIP BETWEEN ASEMPTOMATIC MICROSCOPIC HEMATURIA AND THE DIAGNOSIS OF THE BLADDER TUMOR

Introduction:There is no common opinion that patients presenting with recurrent asymptomatic microscopic hematuria were evaluated especially for for the purpose of predicting bladder tumor. In this study, it was aimed to prospectively assess the potential risk factors that might be effective in predicting bladder cancer in adult patients with asymptomatic microscopic hematuria. Material and Method:We determined the risk factors for recurrent asymptomatic microscopic hematuria in terms of bladder cancer; age, sex, history of urinary tract tumor, history of smoking, risky occupation group were recorded. Urinary cytology, urinary ultrasonography and cystoscopy examinations were performed in all cases. The data were analyzed by single logistic regression analysis test. All hypothesis controls were administered at a significance level of 0.05 (p

PDF

___

Gerber GS, Brendler CB. Evaluation of theUrologic Patient: History, Physical Examination, and Urinalysis. 10th. Ed. Philadelphia: Saunders; Urology 2014,chapter 3 :p.79-110.
Grossfeld GD, Wolf JS , Litwan MS, Hricak H, Shuler CL, Agerter DC, et al. Asymptomatic microscopic hematuria in adults: Summary of the AUA best practice policy recommendations. Am Fam Physician 2001;63 (6): 1145-54.
Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ et al. Diagnosis, evaluation and follow-up of asymptomatic micro hematuria (amh) in adults: AUA Guideline. J Urol 2012; 188 (6 supp): 2473-81.
Turkeri L, Mangir N, Gunlusoy B, Yildirim A, Baltaci S, Kaplan M, et al. Identification of patients with microscopic hematuria who are at greater risk forthe presence of bladder tumors using a dedicated questionnaire and point of care urine test--a study by the members of Association of Urooncology, Turkey. Asian Pac J Cancer Prev 2014; 15(15): 6283-6.
Heller MT, Tublin ME. Insearch of a consensus: evaluation of the patient with hematuria in an era of cost containment. Am J Roentgenol 2014; 202 (6): 1179–86.
Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Skolarus TA, Kim SP, et al. Delays in diagnosis and bladder cancer mortality. Cancer 2010 ; 116 (22): 5235-42.
Mohr DN, Offord KP, Owen RA, Melton LJ III. Asymptomatic microhematuria and urologic disease: a population-based study. JAMA 1986; 256 (2): 224-9.
Bard RH. The significance of asymptomatic microhematuria in women and its economic implications: a ten-years tudy. Arch Intern Med. 1988; 148 (12): 2629-32.
Bourgade V, Drouin SJ, Yates DR, Parra J, Bitker MO, Cussenot O, et al. Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World J Urol 2014; 32 (2): 475-9.
Jung H, Gleason JM, Loo RK, Patel HS, Slezak JM, Jacobsen SJ. Association of hematuria on microscopic urinalysis and risk of urinary tract cancer. J Urol 2011; 185(5): 1698-703.
Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163(2): 524-7.
Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 2011; 185(5): 1621-6.
Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on upper urinarytract urothelial cell carcinoma: 2015 Up date. Eur Urol 2015; 68(5): 868-79.
Witjes JA, Redorta JP, Jacqmin D, Sofras F, Malmström PU, Riedl C, et al. Hexaminol evulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol 2010; 57 (4): 607-14.
Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 2011; 108 (5): 701-5.
Horie S, Ito S, Okada H, Kikuchi H, Narita I, NishiyamaT, et al. Japanese guidelines of the management of hematuria 2013. Clin Exp Nephrol 2014; 18(5): 679–89.
Loo RK, Lieberman SF, Slezak JM, Landa HM, Mariani AJ, Nicolaisen G, et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc 2013; 88(2):129-38.
Wollin T, Laroche B, Psooy K. Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. Can Urol Assoc J 2009; 3 (1): 77-80.
Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, et al. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.World J Urol 2012; 30 (6): 847–52.
Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009; 104 (1): 1436-40.